A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 1, 2013, Pages 23-32

  Belardinelli, Luiz ^a,b   Liu, Gongxin ^a,b   Smith Maxwell, Cathy ^a,b   Wang, Wei Qun ^a,b   El Bizri, Nesrine ^a,b   Hirakawa, Ryoko ^a,b   Karpinski, Serge ^a,b   Li, Cindy Hong ^a,b   Hu, Lufei ^a,b   Li, Xiao Jun ^a,b   Crumb, William ^e   Wu, Lin ^d   Koltun, Dmitry ^c   Zablocki, Jeff ^c   Yao, Lina ^a,b   Dhalla, Arvinder K ^a,b   Rajamani, Sridharan ^a,b   Shryock, John C ^a,b  

^a Gilead Sciences   (United States)

^b Gilead Sciences   (United States)

^c Zenas Technologies ^*  (United States)

^d PEKING UNIVERSITY   (China)

^e ZENAS TECHNOLOGIES LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 6 [4 (TRIFLUOROMETHOXY)PHENYL] 3 (TRIFLUOROMETHYL) [1,2,4]TRIAZOLO[4,3 A]PYRIDINE; ANTIARRHYTHMIC AGENT; CLOFILIUM; FLECAINIDE; GS 967; ION CHANNEL; METHOXAMINE; RANOLAZINE; SEA ANEMONE TOXIN; UNCLASSIFIED DRUG;

ANEMONIA SULCATA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CARDIAC LATE SODIUM CURRENT; CELL ISOLATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENCY; EX VIVO STUDY; FEMALE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HEART VENTRICLE; HEART VENTRICLE ARRHYTHMIA; IN VIVO STUDY; ISOLATED HEART; NONHUMAN; PRIORITY JOURNAL; QRS COMPLEX; SODIUM CURRENT; TORSADE DES POINTES;

ACETANILIDES; ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CARDIOTONIC AGENTS; CNIDARIAN VENOMS; FEMALE; FLECAINIDE; HEART CONDUCTION SYSTEM; LONG QT SYNDROME; MUTATION; MYOCARDIAL ISCHEMIA; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PIPERAZINES; POTASSIUM CHANNEL BLOCKERS; PYRIDINES; QUATERNARY AMMONIUM COMPOUNDS; RABBITS; SODIUM CHANNEL BLOCKERS; TRIAZOLES;

EID: 84871691015     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.198887     Document Type: Article

References (40)

1. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, Cordeiro JM, and Thomas G (2004) Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110: 904-910. (Pubitemid 39136212)
2. Bennett PB, Yazawa K, Makita N, and George AL, Jr (1995) Molecular mechanism for an inherited cardiac arrhythmia. Nature 376:683-685.
3. Boutjdir M and el-Sherif N (1991) Pharmacological evaluation of early afterdepolarisations induced by sea anemone toxin (ATXII) in dog heart. Cardiovasc Res 25:815-819.
4. Chahine M, Plante E, and Kallen RG (1996) Sea anemone toxin (ATX II) modulation of heart and skeletal muscle sodium channel alpha-subunits expressed in tsA201 cells. J Membr Biol 152:39-48. (Pubitemid 26281054)
5. Dhalla AK, Wang WQ, Dow J, Shryock JC, Belardinelli L, Bhandari A, and Kloner RA (2009) Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am J Physiol Heart Circ Physiol 297:H1923-H1929.
6. Follmer CH, Cullinan CA, and Colatsky TJ (1992) Differential block of cardiac delayed rectifier current by class Ic antiarrhythmic drugs: evidence for open channel block and unblock. Cardiovasc Res 26:1121-1130.
7. Galimberti ES and Knollmann BC (2011) Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin. J Mol Cell Cardiol 51:760-768.
8. Haigney MCP, Lakatta EG, Stern MD, and Silverman HS (1994) Sodium channel blockade reduces hypoxic sodium loading and sodium-dependent calcium loading. Circulation 90:391-399.
9. Heinemann SH, Terlau H, and Imoto K (1992) Molecular basis for pharmacological differences between brain and cardiac sodium channels. Pflugers Arch 422:90-92.
10. Hellestrand KJ, Bexton RS, Nathan AW, Spurrell RA, and Camm AJ (1982) Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J 48:140-148. (Pubitemid 12093598)
11. Hondeghem LM, Lu HR, van Rossem K, and De Clerck F (2003) Detection of proarrhythmia in the female rabbit heart: blinded validation. J Cardiovasc Electrophysiol 14:287-294. (Pubitemid 36444471)
12. Ikeda N, Singh BN, Davis LD, and Hauswirth O (1985) Effects of flecainide on the electrophysiologic properties of isolated canine and rabbit myocardial fibers. J Am Coll Cardiol 5:303-310. (Pubitemid 15174086)
13. January CT and Riddle JM (1989) Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ Res 64 :977-990. (Pubitemid 19117651)
14. Ju YK, Saint DA, and Gage PW (1996) Hypoxia increases persistent sodium current in rat ventricular myocytes. J Physiol 497:337-347 Lond. (Pubitemid 26418103)
15. Le Grand B, Vie B, Talmant JM, Coraboeuf E, and John GW (1995) Alleviation of contractile dysfunction in ischemic hearts by slowly inactivating Na1 current blockers. Am J Physiol 269:H533-H540.
16. Le Grand B, Pignier C, Létienne R, Cuisiat F, Rolland F, Mas A, and Vacher B (2008) Sodium late current blockers in ischemia reperfusion: is the bullet magic? J Med Chem 51:3856-3866. (Pubitemid 351956515)
17. Lengyel C, Iost N, Virág L, Varró A, Lathrop DA, and Papp JG (2001) Pharmacological block of the slow component of the outward delayed rectifier current (I(Ks)) fails to lengthen rabbit ventricular muscle QT(c) and action potential duration. Br J Pharmacol 132:101-110. (Pubitemid 32140472)
18. Liu GX, Choi BR, Ziv O, Li W, de Lange E, Qu Z, and Koren G (2012) Differential conditions for early after-depolarizations and triggered activity in cardiomyocytes derived from transgenic LQT1 and LQT2 rabbits. J Physiol 590:1171-1180.
19. Lowe JS, Stroud DM, Yang T, Hall L, Atack TC, and Roden DM (2012) Increased late sodium current contributes to long QT-related arrhythmia susceptibility in female mice. Cardiovasc Res 95:300-307.
20. Maltsev VA, Sabbah HN, Higgins RSD, Silverman N, Lesch M, and Undrovinas AI (1998) Novel, ultraslow inactivating sodium current in human ventricular cardiomyocytes. Circulation 98:2545-2552. (Pubitemid 29001193)
21. Maltsev VA and Undrovinas AI (2006) A multi-modal composition of the late Na1 current in human ventricular cardiomyocytes. Cardiovasc Res 69:116-127. (Pubitemid 41818970)
22. Parikh A, Mantravadi R, Kozhevnikov D, Roche MA, Ye Y, Owen LJ, Puglisi JL, Abramson JJ, and Salama G (2012) Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2. Heart Rhythm 9:953-960.
23. Rajamani S, El-Bizri N, Shryock JC, Makielski JC, and Belardinelli L (2009) Usedependent block of cardiac late Na(1) current by ranolazine. Heart Rhythm 6: 1625-1631.
24. Saint DA (2008) The cardiac persistent sodium current: an appealing therapeutic target? Br J Pharmacol 153:1133-1142.
25. Sicouri S, Antzelevitch D, Heilmann C, and Antzelevitch C (1997) Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome. J Cardiovasc Electrophysiol 8:1280-1290. (Pubitemid 27490696)
26. Song Y, Shryock JC, Wu L, and Belardinelli L (2004) Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 44:192-199. (Pubitemid 38982162)
27. Song Y, Shryock JC, and Belardinelli L (2008) An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am J Physiol Heart Circ Physiol 294:H2031-H2039.
28. Song Y, Shryock JC, Wagner S, Maier LS, and Belardinelli L (2006) Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J Pharmacol Exp Ther 318:214-222.
29. Sossalla S, Kallmeyer B, and Wagner S, et al. (2010) Altered Na(1) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol 55:2330-2342.
30. Undrovinas AI, Belardinelli L, Undrovinas NA, and Sabbah HN (2006) Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol 17 (Suppl 1):S169-S177.
31. Undrovinas A and Maltsev VA (2008) Late sodium current is a new therapeutic target to improve contractility and rhythm in failing heart. Cardiovasc Hematol Agents Med Chem 6:348-359.
32. Ver Donck L, Borgers M, and Verdonck F (1993) Inhibition of sodium and calcium overload pathology in the myocardium: a new cytoprotective principle. Cardiovasc Res 27:349-357. (Pubitemid 23116131)
33. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, and Keating MT (1995) SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 80:805-811.
34. Wang W-Q, Robertson C, Dhalla AK, and Belardinelli L (2008) Antitorsadogenic effects of (+/-)-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2- methoxyphenoxy)propyl]-1- piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther 325:875-881. (Pubitemid 351724316)
35. Wu L, Ma J, Li H, Wang C, Grandi E, Zhang P, Luo A, Bers DM, Shryock JC, and Belardinelli L (2011) Late sodiumcurrent contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization. Circulation 123:1713-1720.
36. Wu L, Rajamani S, Li H, January CT, Shryock JC, and Belardinelli L (2009) Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(1) current in the heart. Am J Physiol Heart Circ Physiol 297:H1048-H1057.
37. Yao L, Fan P, and Jiang Z, et al. (2011) Nav1.5-dependent persistent Na1 influx activates CaMKII in rat ventricular myocytes and N1325 S mice. Am J Physiol Cell Physiol 301:C577-C586.
38. Zaza A, Belardinelli L, and Shryock JC (2008) Pathophysiology and pharmacology of the cardiac "late sodium current.". Pharmacol Ther 119:326-339.
39. Zhao G, Walsh E, and Shryock JC, et al. (2011) Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs. J Cardiovasc Pharmacol 57:639-647.
40. Zimmer T and Surber R (2008) SCN5A channelopathies-an update on mutations and mechanisms. Prog Biophys Mol Biol 98:120-136.